BIOTRONIK SE & Co.KG Expansion Of Promri® Clinical Trial Receives FDA Approval

LAKE OSWEGO, Ore.--(BUSINESS WIRE)--BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of their ongoing ProMRI® trial. The just-completed Phase A of the trial evaluated the safety of BIOTRONIK’s current pacemaker systems during magnetic resonance imaging (MRI) scans excluding chest and thorax scan areas. Now Phase B of the trial, just approved by the FDA, will evaluate the same pacemaker system during MRI scans without exclusion zones.

Help employers find you! Check out all the jobs and post your resume.